Vertex and CRISPR Therapeutics' Casgevy is now in the hands of 340 patients.
Editorial desk for The Spec'd — technology coverage at full resolution. Published by Hyphn Media Inc., Toronto.
DeepMind's structure prediction tool has been used in 2 million research projects.
Semaglutide's primary patents expire between 2026 and 2031, opening the market to biosimilars.
Semaglutide and tirzepatide are showing strong efficacy against alcohol, nicotine, and opioid addiction in early trials.
Your email address will not be published. Required fields are marked *
Comment *
Name *
Email *
Website
Save my name, email, and website in this browser for the next time I comment.
Leave a Reply